deltatrials
Completed PHASE3 INTERVENTIONAL 1-arm NCT02955355

Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP

Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Sponsor: Baxalta now part of Shire

Conditions Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions HYQVIA
Updated 16 times since 2017 Last updated: Aug 5, 2024 Started: Nov 14, 2016 Primary completion: Jul 4, 2023 Completion: Jul 4, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Chronic Inflammatory Demyelinating Polyradiculoneuropathy, this trial is completed. The trial is conducted by Baxalta now part of Shire and has accumulated 16 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Nov 2017 · 9 months · monthly snapshot~Nov 2017 – ~Jun 2018 · 7 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Dec 2019 · 14 months · monthly snapshot~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Oct 2021 · 8 months · monthly snapshot~Oct 2021 – ~May 2022 · 7 months · monthly snapshot~May 2022 – ~Mar 2023 · 10 months · monthly snapshot~Mar 2023 – ~Jun 2023 · 3 months · monthly snapshot~Jun 2023 – ~Aug 2023 · 2 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Aug 2023 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  5. Jun 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE3

▶ Show 11 earlier versions

  1. Mar 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE3

  2. May 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  3. Oct 2021 — May 2022 [monthly]

    Recruiting PHASE3

  4. Feb 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

  5. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE3

  6. Dec 2019 — Jan 2021 [monthly]

    Recruiting PHASE3

  7. Oct 2018 — Dec 2019 [monthly]

    Recruiting PHASE3

  8. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  9. Nov 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

  10. Feb 2017 — Nov 2017 [monthly]

    Recruiting PHASE3

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Baxalta now part of Shire
  • Takeda Development Center Americas, Inc.
Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus C, Denmark , Barcelona, Spain , Belgrade, Serbia , Bordeaux, France , Bron, France , Ciudad Autonoma Buenos Aires, Argentina , Curitiba, Brazil , Denizli, Turkey (Türkiye) , Edmonton, Canada , Gdansk, Poland and 24 more locations